Current trends among pediatric ophthalmologists to decrease myopia progression—an international perspective by Zloto, Ofira et al.
Current trends among pediatric ophthalmologists to decrease myopia progression—an international 
perspective 
Ofira Zloto1,2 & Tamara Wygnanski-Jaffe 1,2 & Sonal K. Farzavandi3,4 & Rosario Gomez-de-Liaño 5 & Derek T. 
Sprunger6 & Eedy Mezer7,8 
Abstract 
Purpose To explore what the current worldwide preferred practice patterns of pediatric ophthalmologists 
are to decrease myopia progression among their patients. 
Methods A questionnaire was sent to all members of supranational and national pediatric 
ophthalmology and strabismus societies. 
Results The questionnaire was fully completed by most respondents 90.10% (847 of 940 responses). Fifty-
seven percent (457) routinely treat to decrease myopia progression. The most common parameter to initiate 
treatment was a myopic increase of 1 diopter/year or more (74.8%, 246). Seventy percent (345) prescribed 
eye drops. Atropine 0.01% was the most popular (63.4%, 277) followed by atropine 1% (10.9%, 48) and 
atropine 0.5% (8.9%, 39). Eighty-six percent (394) of the respondents advised to spend more time outdoors, 
to reduce the amount of time viewing screens (60.2%, 277), and cutback the use of smart phones (63.9%, 294). 
Conclusions Most pediatric ophthalmologists treat to decrease myopia. They employ a wide variety of 
means to decrease myopia progression. Atropine 0.01% is the most popular and safe modality used 
similarly to recent reports. However, there is no consensus when treatment should be initiated. Further 
prospective studies are needed to elucidate the best timing to start treatment and the applicability of recent 
studies in the Asian population to other ethnic groups. This will improve the ability to update pediatric 
ophthalmologist with evidenced-based treatment options to counter the myopia epidemic. 
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 Introduction 
 
Myopia is the most common visual disorder with 
increasing prevalence rates worldwide. Recent 
studies have shown that approximately 80% to 
90% of Asian school children are my- opic [1–5]. 
In North America and in Europe, the prevalence of 
myopia has now increased to 40–60% in younger 
adults [6, 7]. Holden et al. reported that myopia 
and high myopia will show a significant increase 
in prevalence globally, affecting nearly five 
billion people and one billion people, 
respectively, by 2050. This would correspond to a 
2.6-fold increase in the number of people with 
myopia from to 2010 to 2050 [8]. 
High myopia is a leading cause of irreversible 
visual impairment and can cause blindness even in 
children [9]. Myopia imposes heavy 
socioeconomic burdens on individuals and 
countries. Health economic studies reported that 
the medical cost of myopia far exceeded those of 
other major eye conditions such as retinal diseases 
and glaucoma [10, 11]. 
 
 
  
  
 
The treatment to decrease the rate of myopia 
progression spans three modalities: 
pharmacological, optical, and behavioral. Each of 
these modalities includes numerous possibilities 
with different impact on myopia progression [12–
16]. 
Nevertheless, there is no consensus to what is the 
best way to treat in order to prevent myopia 
progression, when to begin treatment, and in whom 
treatment should be tailored according to one’s 
genetic background [17]. 
The purpose of the study was to explore the 
different interventions utilized by pediatric 
ophthalmologists worldwide to decrease the 
progression of myopia. This could map the cur- 
rent extent and type of involvement of this group of 
healthcare professionals to confront the epidemic 
of myopia affecting children and teenagers. 
 
 
 
Methods 
 
Survey population and questionnaire 
 
An email communication was sent to all members 
of the International Pediatric Ophthalmology 
and Strabismus Council (IPOSC) and the 
American association for pediatric ophthalmology 
and strabismus (AAPOS) through IPOSC and 
AAPOS secretariat in December 2016. Responses 
were received until June 2017. The email included 
a web link to a survey (created on 
www.surveymonkey.com), explaining the purpose 
of the study, and offered a contact email and phone 
number that allowed the respondents to seek 
further clarification if needed. The 
questionnaire included 17 questions 
(Supplemental 1: English version; Supplemental 2: 
Spanish version). The required information 
included the characteristics of the myopic patients, 
personal preference of treatment, and the various 
interventions employed to slow the progression of 
myopia. 
The questionnaire was also sent via the AAPOS 
(1801 members) list server on three occasions and 
through the International Strabismological 
Association (ISA)-308 mem- bers, the Asia-
Pacific Strabismus and Paediatric 
Ophthalmology Society (APSPOS)-152 members, 
and various national societies secretariats to their 
members. This included countries in the Middle 
East, India (via the Society of Pediatric 
Ophthalmology and Strabismus of India, SPOSI), 
Far East Asia, and Latin America (via the Congress 
of the Latin American Council of Strabismus, 
CLADE). The total number of members from the 
different organizations cannot accurately be 
assessed because many respondents are members of 
more than one organization, for example, 
membership in a national as well as one or more 
supranational organizations. The questionnaire 
was translated from English to Spanish, and the 
introduction was translated to Chinese and Korean. 
  
For those in India whose email was not 
available, the sur- vey was sent as a message via 
the WhatsApp application (WhatsApp Inc., CA, 
USA). 
All authors declared no financial or non-
financial conflict of interest, and no formal 
consents were required as the information 
obtained through the questionnaire did not refer 
to a specific patient but rather to the general 
clinical treatment patterns of the respondent. The 
study adhered to the principles outlined in the 
Declaration of Helsinki and was approved by the 
local institutional review board (IRB) of Sheba 
Medical Center. 
 
 
Statistical analysis 
 
Statistical analysis, including distribution, was 
performed with the JMP Statistical Discovery 
Software 7.0 (SAS Institute, Cary, NC, USA). 
The overall significance level was set to an alpha 
of 0.05. 
 
 
 
Results 
 
Nine hundred forty members of the various 
pediatric ophthalmology and strabismus 
organizations responded to the questionnaire. The 
survey was fully completed by 90.1% (847) of the 
respondents that had participated in the survey. 
Almost one fifth of the responders (18.1%, 163 
of 899 who replied to this question) had practiced 
pediatric ophthalmology for less than 5 years, 
15.7% (141) for 5 to 10 years, 16.79% 
(151) for 10 to 15 years, 14.1% (127) for 15 to 
20 years, 13.2% (119) for 20 to 25 years, and 
22.0% (198) for more than 25 years. 
The place of employment was a multichoice 
question. Accordingly, 1005 choices were 
received from 940 respondents. Roughly a third 
(37.5%, 377) of respondents work at a 
university-based hospital, 23.1% (232) 
work at a multispecialty private group practice, 
21.7% (218) in a hospital, and 17.7% (178) at a 
group practice. 
Most responses came from North America 
(26.8%, 227), Far East Asia (16.6%, 141), and 
Europe (16.3%, 138). The complete geographical 
distribution is depicted in Table 1. 
The three countries with most replies were the 
USA (21.3%, 200), India (8.6%, 81), and Japan 
(5.7%, 54). The 
distribution of all countries of residence of the 
respondents is summarized in Table 2. 
Reports of more than one ethnic background of 
the patients in the survey were allowed. Therefore, 
1764 choices were chosen by the 940 respondents: 
Caucasian descent (26.1%, 460), Indian (23.7%, 
419), Far East Asian (20.1%, 355), 
African (12.4%, 219), Arab (11.2%,  197),  and  
Hispanic 
(6.5%, 114). 
  
 
Table 1 Geographical distribution of 847 
respondents 
  
Continent Percentage of 
respondents 
(numbers) 
  
North America 26.8% (227) 
Far East 16.6% (141) 
of myopia progression (57.0%, 457 out of 801 
who have answered this question). An average of 
57% of respondents advocated treatment to 
decrease the rate of myopia progression. This 
ranged considerably from 89% in Australia and 
New Zealand to 12% in Africa (Table 3). 
Most of them have been treating patients for the 
past year 
Europe 16.2% (138) or two (42.7%, 215 out of 504 responses for this 
question), 
Central Asia 14.7% (125) 28.4% (142) have been treating patients for 3 to 5 
years, 
South America 10.3% (87) 12.4% (61) have been treating patients for 6 to 10 
years, and 
Middle East 8.5% (72) 16.4% (86) have been treating for more than 10 
years. 
Central America 2.4% (21)  
Australia 2.0% (17) 
Africa 1.9% (16) 
New Zealand 0.3% (3) 
  
 
Treatment for decreasing myopia 
 
The majority of pediatric ophthalmologists, who 
have participated in the current study, routinely 
treat to decrease the rate 
 
When treatment should be initiated 
 
The most common parameter in the current study 
to initiate treatment was when respondents 
documented an increase in myopia at an average 
rate of 1 diopter/year or more (53.4%, 246 out of 
461 who have replied to this question). Twenty-one 
percent (96) initiated treatment as soon as they have 
identified myopia at an average age of 5.3 years of 
age (median 5, range 
 
Table 2 Country distribution 
Country Percentage of 
respondents for 
each country (numbers) 
USA 21.3% (200) 
India 8.6% (81) 
Japan 5.7% (54) 
Taiwan 3.6% (34) 
Spain 3.5% (33) 
Republic of Korea, Israel 3.2% (30) 
Canada 2.6% (25) 
Chile 2.2% (21) 
  
Argentina, Islamic Republic of Iran 2.1% (20) 
Brazil 1.9% (18) 
Australia, Mexico 1.8% (17) 
China 1.4% (13) 
Singapore 1.2% (11) 
Azerbaijan, Italy, Turkey 1.1% (10) 
Bangladesh, Britain 0.9% (9) 
Philippines 0.8% (8) 
Belgium, Egypt, Portugal, Venezuela 0.7% (7) 
Colombia, France, Nigeria, Peru, Romania, Russia 0.6% (6) 
Denmark, Germany, Indonesia 0.5% (5) 
Croatia, Greece, Saudi Arabia, Ukraine 0.4% (4) 
Albania, Austria, Bolivia, Bulgaria, 
Dominican Republic, Ecuador, Jordan, New 
Zealand 
El Salvador, Hong Kong, Hungary, Malaysia, 
Netherlands, Serbia, Switzerland, Thailand, 
Vietnam 
Afghanistan, Angola, Argentine, Bahrain, 
Bharat, Dubai, Finland, Guatemala, Ireland, 
Lithuania, Macedonia, Myanmar, Nepal, 
Norway, Oman, Paraguay, Puerto Rico, 
Qatar, South Africa, Sweden, Tunisia 
0.3% (3) 
 
0.2% (2) 
 
0.1% (1) 
Not specified 11.1% (94) 
  
 
Table 3 How many pediatric ophthalmologists 
advocate treatment to decrease the rate of myopia 
progression in each geographical region 
 
Continent Treatment 
recommende
d* 
Treatment 
not 
recommen
ded* 
Australia and New 
Zealand 
88.9% (16) 11.1% (2) 
Far East 70.2% (99) 29.8% 
(42) 
North America 63.8% (143) 36.2% 
(81) 
Central America 57.1% (12) 42.8% (9) 
All respondents 57.0% (457) 42.9% 
(344) 
Central Asia 56.5% (65) 43.5% 
(50) 
South America 54.8% (46) 45.2% 
(38) 
Middle East 41.3% (31) 58.7% 
(44) 
Europe 38.3% (44) 61.7% 
(71) 
Africa 12.5% (1) 87.5% (7) 
*Percentage (number) of respondents 
 
2 to 8). Fourteen percent (62) initiated treatment 
as soon as they have identified myopia above 3.5 
diopters. 
Most respondents (51.0%, 242 out of 474 
responses to the question) did not know at what age 
response to treatment was most effective to 
decrease the rate of myopia progression. The 
average reported age to treat most effectively was 
9.71 years old (median 9.75, range 1 to 35). Figure 
1 summarizes all the responses to this query. 
 
Treatment modalities 
 
The most effective modality was thought to be 
pharmacological treatment (54%, 266 out of 493 
replies to the question), followed by behavioral 
treatment (24.7%, 122) and optical treatment 
(21.3%, 105). 
 
Pharmacological treatment 
 
Most (70%, 345 out of 493 who have responded to 
this question) prescribed eye drops in order to slow 
the progression of myopia. The average age eye 
drops were initiated was 5.23 (median was 5, range 
0.5 to 16 years old). More than one option was 
allowed, which resulted in 439 answers from 345 
respondents to this question. The most popular 
medication was atropine 0.01% (63.5%, 279), 
atropine 1% (10.9%, 48), 
and atropine 0.5% (8.9%, 39). Figure 2 summarizes 
the distribution of all the pharmacological agents. 
Atropine 0.01% was the pharmacological 
treatment with the highest number of respondents 
that have not discontinued treatment in any of their 
patients receiving these eye drops (63.8%, 178). A 
few patients reported a rebound effect after 
discounting the use of atropine 0.05% (66.7% had no 
rebound effect). In contrast, all patients that 
applied pirenzepine, homatropine, and atropine 
0.3% suffered from a rebound effect upon cessation 
of this medication. The complete list of 
  
typical eye drops utilized by the respondents is 
displayed in Table 4. 
 
Optical correction 
 
The type of optical correction was a multichoice 
question. Therefore, 791 answers were received 
from 393 responses to this question. Thirty-four 
percent (268) of the respondents prescribed full-
correction spectacles, followed by spectacle 
with progressive addition lenses (11.6%, 92), 
and orthokeratology (10.5%, 83). Those and 
other types   of optical correction are 
summarized in Fig. 3. 
 
Behavioral recommendation 
 
The type of behavioral recommendation was also a 
multichoice question. Therefore, 1396 answers 
were received from 439 ophthalmologists. Most 
respondents recommended to spend more time 
outdoors (27.9%, 390), to lessen the usage of 
smartphones (20.8%, 290), and to watch monitor 
screens and the television less frequently (19.6%, 
274). All the recommendations are delineated in 
Fig. 4. 
 
 
Discussion 
 
Myopia is one of the most common ocular 
disorders in the world [6, 18] with a different 
incidence worldwide [16, 19]. This worldwide 
survey summarizes the various approaches of 
pediatric ophthalmologists to treatment to 
decrease myopia progression. 
Nine hundred forty pediatric ophthalmologists 
participated in the survey. Most of them were 
seasoned professionals with over 10 years of 
experience in pediatric ophthalmology. Not 
surprisingly, almost 60% of respondents worked 
at a hospital mostly academically affiliated, thus 
perhaps increasing the number of early adaptors 
of new ways to treat including to decrease 
myopia progression. 
There was a large representation from North 
America, Far East, Europe, and central Asia with 
the smallest number of reports from Australia, 
New Zealand, and Africa. This is mainly due to 
the lower number of doctors practicing medicine 
in these regions either because of a smaller 
population in Australia or due to a scarcity of 
medical doctors in Africa [20, 21]. 
The ethnic diversity of patients treated by the 
respondents covered mostly those of Caucasian, 
Indian, or Far East Asian descent, due to the 
geographical locations of the respondents. China 
was specifically underrepresented with only 13 
ophthalmologists due perhaps to language as well 
as other barriers preventing this survey from 
reaching a significant number of potential 
respondents. Nevertheless, this is the first survey to 
include multi-international centers around the 
world. 
  
 
Fig. 1 The age at 
which the respondents 
deemed the treatment to 
decrease myopia to be 
most effective 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment of myopia at an early stage before it 
increases to high myopia can significantly reduce 
the risk of retinal detachment, glaucoma, cataract, 
and macular degeneration. All these conditions 
are much more prevalent in high my- opia and can 
lead to blindness [9]. Therefore, it was 
disconcerting to find out that about 43% of the 
respondents in the current survey do not routinely 
treat to decrease myo- pia. More specifically, 
almost 90% of the respondents in Africa, and 
around 60% in Europe and Middle East, do not 
treat routinely to decrease myopia. People of 
African 
descent are known to have has less myopia 5–7% 
in aver- age [8, 22] as well as residents of the 
Middle East of Arab descent (1.45% in rural areas 
and 3.16% in urban area) [22]. Therefore, 
preventing myopia in those regions does not cause 
as much concern as in Far East Asia where the 
prevalence of myopia in 2010 was 47% and is 
predicted to be 65.3% in 2050 [8]. Li et al. found 
already that the prevalence rates of myopia in 
central China are 67.3% in grade 7 [23]. There 
have recently been some epidemiological reports 
from Europe about an increase in the incidence of 
 
 
  
 
Fig. 2 Topical medications used to decrease myopia progression 
  
 
Table 4 Rebound effect of eye drops prescribed by pediatric ophthalmologists to decrease the progression 
of myopia 
 
Eye drops Respondents that 
have not 
discontinued 
treatment in any of 
their patients 
Respondents whose 
patients have 
discontinued treatment 
 
Rebound effect 
experienced after 
 
 
 
No rebound effect 
after 
Total number of 
respondents whose 
patients received 
treatment 
  discontinuing eye drops* 
discontinuing eye 
drops*  
Latanopr
ost, 
travopr
ost 
Atropine 
100% (1) 
 
63.8% (178) 
0% (0) 
 
36.2% (101) 
 1 
 
279 
0.01%  52.5% (53) 47.5% (48)  
Timolol 60% (3) 40% (2)  5 
  0% (0) 100% (2)  
Pirenzepin
e 
33.3% (1) 66.7% (2)  3 
  100% (2) 0% (0) 0% (0) 
Atropine 
1% 
25% (12) 75% (36)  48 
  50% (18) 50% (18)  
Tropicami
de 
25% (7) 75% (21)  28 
  42.9% (9) 57.1% (12)  
Atropine 
0.5% 
20.5% (8) 79.5% (31)  39 
  74.2% (23) 25.8% (8)  
Atropine 
0.1% 
18.7% (3) 81.3% (13)  16 
  69.2% (9) 30.8% (4)  
Cyclopent
olate 
14.3% (2) 85.7% (12)  14 
1%  58.3% (7) 41.7% (5)  
Atropine 
0.3% 
0% (0) 100% (2)  2 
  100% (2) 0% (0)  
Atropine 0% (0) 100% (3)  3 
0.05%  33.3% (1) 66.7% (2)  
Homatropi
ne 
0% (0) 100% (1)  1 
  100% (1) 0% (0)  
Total 49% (215) 51% (224)  439 
  
  56% (125) 44% (99)  
*(%), percentage out of total number of respondents, whose patients have discontinued eyes’ drops 
 
 
myopia and high myopia from 17.8 to 23.5% in 
those born between 1910 and 1939 compared with 
1940 and 1979 and predicted to increase from 
28.5% in 2010 to 56.2% in 2050 [8, 24]. However, 
it seems that pediatric ophthalmologists in Europe 
have yet to increase their active participation to 
face the challenge of the myopia epidemic. 
This study shows that treatment to decrease 
myopia progression has picked up in recent years 
as more pediatric ophthalmologists started to get 
involved and provide this service. This may be 
related to the increase in publications on this topic. 
A MEDLINE database search utilizing myopia as 
a keyword yielded 203 articles published during 
2007, 242 papers released during 2012, and 306 
studies 
during 2017. 
In the current survey, more than half of the 
respondents opted to initiate treatment when 
myopia increased more than 1 D/year. This is in 
accordance with some of the published 
literature [25] while others started when myopia 
progression of − 0.50 D/year or more [26]. 
There is no consensus in the literature when to 
start treating to decrease myopia [25, 27, 28]. 
Similarly, most of the respondents in this survey did 
not know at what the age the response to treatment 
was most effective. In most of the study, the 
average was 6 to 12 years old [24, 26, 27] which is 
in accordance with the average age that was found 
in this study  (10 years old). 
Currently, there are no accepted guidelines what 
is the best medication suited to lessen myopia 
progression. In 2011, the Cochrane Database 
examined the published evidences of the 
progression of nearsightedness in myopic children. 
They examined eye drops such as atropine and 
pirenzepine versus under correction of 
nearsightedness versus multifocal spectacles and 
contact lenses. They concluded that the most 
likely effective treatment to slow myopia 
progression thus far is anti- 
  
 
 
 
 
 
 
Fig. 3 Type of optical correction used to decrease myopia progression 
 
 
muscarinic topical medication [29]. During the 
years, atropine for decreasing progression of 
myopia was utilized in different dosages (1, 0.5, 
0.3, 0.1, and 0.01%). Higher dosages had a 
stronger initial effect but caused more side effects 
such as light sensitivity and accommodative 
insufficiency and furthermore caused a rebound 
effect [12]. Atropine 0.01% was found to have the 
same efficacy after 5 years with few side effects 
without a rebound effect after cessation [12, 26]. 
Due perhaps to these publications, 70% of the 
respondents who choose to utilize 
pharmacological treatment chose atropine 0.01%. 
In this survey, atropine 0.01% was the 
pharmacological treatment with the highest 
number of respondents that have not discontinued 
treatment probably because of its low side effects. 
 
Tong et al. [30] and Chia et al. [31] reported about 
rebound effect after treatment cessation of 
atropine. They found a direct correlation between 
the dosage of atropine and the progression of 
myopia after discontinuation of this treatment. 
This was also the trend in this survey. 
In this survey, only 16.64% were of Far East 
Asia decent, sharing the same ethnic background 
as the subjects treated in the ATOM studies [12]. 
Further studies of subjects from other ethnic 
groups are needed to verify the applicability of 
these studies to other parts in the world. 
Huang et al. performed a network meta-analysis of 
interventions proposed to reduce myopia 
progression. Progressive addition spectacle lenses 
were effective in reducing progression of the 
refraction. Orthokeratology, peripheral defocus 
modifying
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
 
  
Fig. 4 Behavior modifications recommended to decrease myopia progression 
  
 
contact lenses, and progressive addition spectacle 
lenses (PAL) were effective in reducing progression 
of axial length [13]. In contrast, only about a quarter 
of the respondents who chose optical correction for 
their patients suggested the use of any one of the 
types proven to be significantly effective. This may 
be due to multiple reasons: the moderate effect of 
some of these modalities (PAL), the high cost of 
multifocal spectacles and special contact lenses 
[32], and the increased risk of severe corneal 
infections in children utilizing overnight contact 
lenses 
[33] as well the low availability of commercially 
approved contact lenses with peripheral defocusing 
[34]. 
Close to 70% of pediatric ophthalmologists 
who recommended to modify behavior to decrease 
myopia progression choose to recommend more 
outdoor activity and less time using monitors and 
reading from small screens at near in order to 
prevent progression of myopia [4, 35]. This is 
supported by studies that showed the benefit of 
these changes in type of activity [36]. The most 
popular behavioral recommendation in this survey 
was to spend more time outdoors which was 
proven also as reducing the incidence of myopia in 
different populations [5, 37]. In addition, it has 
been reported that behavioral interventions such as 
decreasing the duration of near work are of benefit 
[38, 39]. 
The replies to the questionnaire of Wolffsohn et 
al. were in contrast to the responses to THE current 
survey. In their questionnaire, the respondents 
rated orthokeratology as the most effective 
method of myopia control, followed by increased 
time outdoors and pharmaceutical approaches. 
This may be due to the fact that most of the 
respondents to this questionnaire were 
optometrists (72.4%) and only 18% were ophthal- 
mologists. Thus, it stands to reason that they 
advocated optical correction and advocated much 
less the utility of pharmaceutical approaches as 
well as behavior modification [32]. In an- other 
survey that was conducted among members of the 
Korean Ophthalmological Society, regarding 
popular treatment options to decrease myopia 
progression in children, the majority did not support 
prescribing orthokeratology. Topical atropine was 
not considered effective. Most practitioners chose 
to prescribe glasses with full cycloplegic correction 
[40]. The Korean survey did not deal with many 
treatment options, but similarly to the current 
survey, it shows that most respondents prescribed 
full-correction lenses and not progressive addition 
lenses that are known to moderately retard the rate 
of progression of myopia [8]. The study was 
published in 2011 before treatment with atropine 
0.01% became popular- ized with less rebound and 
less side effects than treatment with atropine in a 
higher concentration [41]. 
There are several limitations to our study: First 
of all, this was a survey of only pediatric 
ophthalmologists. Therefore, it may not reflect the 
clinical practice of other ophthalmologists who 
treat pediatric myopia. Secondly, there was an 
unequal representation of ophthalmologists from 
different parts of the globe and various ethnic 
  
backgrounds. The views from such countries 
especially from China are underrepresented in 
this study. However, this study is the first to 
include a high number of inter- national centers 
in a single study, not just sampling a certain 
continent or ethnic group. 
In conclusion, we hope that as time goes by, 
more pediatric ophthalmologists will join the 
worldwide effort to decrease the progression of 
myopia utilizing evidence-based treatment 
modalities. Nevertheless, not everyone is an early 
adopter of treatment modalities, 40% still do not 
treat at all, and some choose treatments that have 
not been shown to be significantly effective. One 
hopes to see more pediatric ophthalmologist treat 
to decrease the progression of myopia among 
their pa- tients as additional studies guide us what 
is the best timing to initiate various types of 
treatment as well as the applicability of the 
treatment of atropine 0.01% in Far East Asians to 
other ethnic groups. The most popular treatment 
modalities in this study were topical application 
of atropine 0.01% eye drops, full optical 
correction with spectacles, and encouragement of 
patients to spend less time in front of monitors and 
television screens as well as smartphones and 
tablets and increase time spent outdoors. As more 
eye care professionals in general and pediatric 
ophthalmologists in particular start to treat to de- 
crease myopia progression, these endeavors 
would hopefully help moderate the global 
epidemic of myopia. 
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